H. Lundbeck A/S (HLUN-B.CO)
Copenhagen · DKK · Healthcare · Drug Manufacturers - Specialty & Generic
DKK 52.25 (-0.38%) as of
Key statistics
- Market cap
- 51.84B
- P/E (TTM)
- 13.33
- Forward P/E
- 8.48
- EPS (TTM)
- 3.92
- Dividend yield
- 2.19%
- 52-week range
- 35.30 – 53.10
- Beta
- 0.24
- Revenue (TTM)
- 25.96B
- Profit margin
- 15.16%
- Analyst target
- DKK 49.79
- Volume
- 727.04k
About H. Lundbeck A/S
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson's disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson's disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Valby, Denmark
- Employees
- 5,000
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.